Tech Company Financing Transactions
Padlock Therapeutics Funding Round
On 12/19/2014, Padlock Therapeutics announced $23 million in Series A funding from Atlas Venture and private investors.
Transaction Overview
Company Name
Announced On
12/19/2014
Transaction Type
Venture Equity
Amount
$23,000,000
Round
Series A
Investors
Atlas Venture (Lead Investor) (Bruce Booth)
Proceeds Purpose
Padlock plans to use the proceeds from this financing to deepen its understanding of the role of protein-arginine deiminases (PADs) in autoimmune disease and to advance its pipeline of PAD-directed therapeutics.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
25 1st St. 303
Cambridge, MA 02141
USA
Cambridge, MA 02141
USA
Phone
Website
Email Address
Overview
At Padlock, we're taking a whole new approach to treating destructive autoimmune diseases by extinguishing autoantigens at their source instead of targeting the immune system like current medicines.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Michael Gilman
Chief Scientific Officer
Rajesh Devraj
Browse more venture capital transactions:
Prev: 12/19/2014: RealConnex venture capital transaction
Next: 12/19/2014: NextLesson venture capital transaction
Share this article
About Database of VC Transactions
We do our best to record tech company VC transactions. VC investment data records on this site come from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs